This patient was treated with combined radiotherapy and idelalisib which is a selective PI3K p110δ inhibitor, that has effectively been used in the treatment of chronic lymphocytic leukemia (CLL), B-ALL and Hodgkin lymphoma (HL) [16]. Here, PIK3CD is linked to Hodgkins lymphoma.